MedPath

A Research About Nutrition Impact for Local Advanced Nasopharyngeal Carcinoma Patients

Phase 4
Conditions
Malignant Neoplasm of Nasopharynx
Interventions
Dietary Supplement: Nutrison
Registration Number
NCT02948699
Lead Sponsor
Zhejiang Cancer Hospital
Brief Summary

The chemo-radiotherapy for the local advanced nasopharyngeal carcinoma patients will induce the mucosal ulcer and damage salivary glands. Consequently, it can disturb the nutrition conditions and clinical outcomes of patients. This research tries to evaluate the nutrition status at the baseline, before and after radiotherapy, during the follow-up by the body mass index, hematological indexes, immunological indexes, and nutrition questionnaires including PG-SGA and NRS 2002. Through the evaluation of two different nutritional interventions, the investigators aim to find an optimized assessment model and the best nutrition support patterns.

Detailed Description

All nasopharyngeal patients received radical treatment including neo-adjuvant chemotherapy and concurrent chemo-radiotherapy. At the beginning, the investigators assign patient to experimental and control groups randomly. Patients in experimental group received standard nutritional support by adding NUTRISON. Control patients will give conventional nutritional guidance. The investigators collected all the nutritional indexed at first visit, before and after radiotherapy, 1, 3, 6, 9, 12 months after radiotherapy. All these data will be set into statistical software to produce an optimized model for clinical practice.

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
114
Inclusion Criteria
  1. Histologically conformed Initial nasopharyngeal carcinoma
  2. Patients can feed through the mouth.
  3. ECOG (Eastern Cooperative Oncology Group) : 0-2.
  4. No history of chemo-radiotherapy, immuno-therapy or biotherapy.
  5. Normal hemodynamic indices before the recruitment (including white blood cell count>4.0×109/L, neutrophil count>1.5×109/L, platelet count >100×109/L, hemoglobin≥90g/l, normal liver/kidney function).
  6. Informed consent signed.
Exclusion Criteria
  1. History of malignant tumors.
  2. Any severe complications contraindicated chemotherapy or radiotherapy.
  3. Medical history of central nervous system, cognitive or psychological diseases;
  4. Pregnant or nursing women.
  5. Patients with mental disease cannot complete the questionaire.
  6. Patients refused the informed consent.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Nutrition supportNutrisonNutrison was added to regular diet while the patients can be fed through mouth. Nutrison will replace regular diet by NG or PEG while the patients can not eat for serious oral mucositis.
Primary Outcome Measures
NameTimeMethod
Overall survival5 years

From the first treatment to the death of any causes

Secondary Outcome Measures
NameTimeMethod
Progress free survival5 years

From the first treatment to the progress of diseases

Trial Locations

Locations (2)

Zhejiang Cancer Hosptial

🇨🇳

Hangzhou, Zhejiang, China

Zhejiang Cancer Hospital

🇨🇳

Hangzhou, Zhejiang, China

© Copyright 2025. All Rights Reserved by MedPath